Eagle Bancorp Amends Q4 2025 Earnings Presentation with Updated Capital Ratios and Loan Details
EGBN sits 83% above its 52-week low of $15.03.
Summary
Eagle Bancorp filed an amendment to its Q4 2025 earnings presentation, updating its CET1 ratio, correcting the top 25 loans list, and adding a summary of its Commercial & Industrial portfolio.
Key Events · Corporate Governance and Compliance · EGBN
-
Updates Capital Adequacy Ratio
The company updated its CET1 ratio on multiple slides (5, 7, 17, and 22) to reflect the correct figure to be reported in its FR Y-9C report, a key regulatory capital metric for banks.
-
Corrects Top 25 Loans Listing
Slide 26 of the earnings presentation was revised to accurately list the company's top 25 loans as of December 31, 2025, providing clearer insight into loan concentrations.
-
Adds Commercial & Industrial Portfolio Summary
A new slide (Slide 27) was added to summarize the Commercial & Industrial (C&I) portfolio, offering additional detail on this segment of the loan book.
-
Follows Recent Earnings Report
This amendment follows the original 8-K filing on January 21, 2026, which reported a net income of $7.6 million for Q4 2025, a significant turnaround from a prior net loss.
Analysis · EGBN · Finance
This 8-K/A filing provides important updates and corrections to the slide presentation previously filed with the Q4 2025 earnings report on January 21, 2026. For a financial institution, accurate reporting of capital adequacy ratios like CET1 and detailed loan portfolio information is critical for investor assessment of financial health and risk. The amendment clarifies key financial metrics and provides new insights into the Commercial & Industrial loan portfolio, which can influence investment decisions.
At the time of this filing, EGBN was trading at $27.49 on NASDAQ in the Finance sector, with a market capitalization of approximately $834.9M. The 52-week trading range was $15.03 to $29.26. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.